K-Bio Lab Hub breaks ground in Incheon's Songdo

South Korea has broken ground on the K-Bio Lab Hub, a one-stop support facility for biotech startups covering research and development, investment attraction and global expansion, at Songdo in Incheon.

The Ministry of SMEs and Startups held a groundbreaking ceremony Wednesday at Yonsei University's International Campus in Songdo, Incheon.

The K-Bio Lab Hub is modeled on LabCentral, a Boston-based biotech startup support organization, and is designed to serve as shared infrastructure for biotech ventures. The project was confirmed in March 2021, and Songdo was selected as the final site through a public competition. Construction began after a preliminary feasibility study in August 2022 and years of architectural design work.

Yonsei University is providing the land, while Incheon city is covering construction costs. The Ministry of SMEs and Startups will fund operations, high-cost research equipment and R&D programs. The structure lets biotech startups share research facilities and equipment that would be difficult to acquire individually, with support spanning technology development through commercialization.

The K-Bio Lab Hub is scheduled for completion in November 2028, at which point 60 biotech startups will move in. The first and second floors will house an operations control room and a zone for high-cost specialized equipment, floors three through seven will provide 50 spaces for early-stage companies, and floors eight and nine will offer 10 spaces for growth-stage firms.

Research equipment will be added in phases. The ministry plans to introduce 17 types and 24 units of general-purpose research equipment at a temporary space on Yonsei University's International Campus by October. By the time the building is complete, a total of 59 types and 134 units of advanced research equipment will be in place.

Songdo is already home to major biotech companies including Celltrion, Samsung Biologics, SK Bioscience and Lotte Biologics, as well as Yonsei Severance Hospital and related infrastructure. The ministry plans to use the K-Bio Lab Hub as a hub connecting startups with universities, anchor companies, hospitals and venture capital firms to promote joint R&D and investment.

Starting in 2029, the hub will channel a total of 41.4 billion won ($30.5 million) to 60 resident companies, covering candidate substance discovery, preclinical and clinical trials, regulatory approval and investment attraction.

Support will not be limited to resident companies. Biotech startups that do not move in can still access the hub's research infrastructure, venture capital networks and data analysis services through a membership program. The ministry plans to reinvest revenue generated through the membership program to build a financial foundation that allows the hub to operate independently after government funding ends.

The biotech industry expects the K-Bio Lab Hub to ease the heavy R&D cost burden on early-stage companies. Because the sector requires expensive equipment and specialized personnel from the earliest stages of drug development, startups typically struggle to build their own research base. Analysts say the hub's success will hinge on its ability to forge connections between technology development and follow-on joint research, investment and commercialization — particularly given the concentration of large biotech firms, universities, hospitals and investors already in Songdo.

"The K-Bio Lab Hub will become the core cradle where South Korea's biotech startups grow into global unicorn companies," Minister of SMEs and Startups Lee So-young said. "Starting from this groundbreaking, we will bring together the capabilities of our partner organizations to build a world-class biotech startup hub."